查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715449

代谢紊乱药物市场按治疗类别、疾病类型、治疗领域、给药途径、患者族群、最终用户和分销管道划分－2025-2030 年全球预测

Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

代谢紊乱治疗药物市场预计在 2023 年达到 698.4 亿美元，到 2024 年将以 8.35% 的复合年增长率增长至 755.5 亿美元，到 2030 年将达到 1224.9 亿美元。

主要市场统计数据
基准年2023年 698.4亿美元
预计2024年 755.5亿美元
预测年份 2030 1224.9亿美元
复合年增长率（%） 8.35%

在当前的医疗保健创新领域，代谢紊乱治疗已成为研究人员、临床医生和政策制定者关注的重点领域。尖端科学研究与临床应用的空前结合重新点燃了人们对代谢和内分泌疾病有效治疗方法的兴趣。随着科学突破在基因编辑、酵素控制和个人化医疗领域不断取得新进展，监管机构和医疗保健提供者之间的对话也日益成熟。本执行摘要深入探讨了重塑治疗格局的变革趋势、患者需求与疾病复杂性之间的界限以及行业领先企业之间的竞争动态。全面了解这些因素对于相关人员应对复杂情况、优化资源配置和利用这个充满活力的市场中的新机会至关重要。

本报告提供了市场趋势的整体情况，并指出了行业领导者和市场参与企业面临的策略挑战。利用最新的进展和市场数据，该分析强调了代谢紊乱治疗如何从传统方法演变为以患者为中心的现代解决方案。该分析旨在探索严谨的科学研究与稳健的市场策略之间的相互作用，为决策者提供推动这一快速发展产业永续成长的蓝图。

改变治疗格局的变革

近年来，由于生物医学研究的创新和监管环境的变化，代谢疾病治疗领域发生了重大变化。个人化医疗的出现和数位技术的融合正在加速从传统治疗模式转向更有针对性的治疗方法的演变。在分子生物学和真实世界证据的发展推动下，市场正在经历重大变化，这些变化正在影响治疗方案和临床最佳实践。基因治疗、酵素替代疗法和小分子疗法的科学进步共同帮助简化了患者照护并改善了临床结果。

基因序列测定和生物资讯技术的突破使研究人员能够详细阐明疾病机制，从而发现新的生物标记和治疗标靶。这些技术创新大大缩短了从研究到商业化的週期。随着治疗方案不断改进以解决复杂的代谢紊乱，数据分析和病患监测的融合正在稳步重新定义治疗模式。多学科见解的整合创造了设计既有效又具有成本效益的强有力治疗方法的机会，与全球医疗保健系统的策略重点保持一致。

此外，不断发展的监管政策正在创造一个鼓励快速创新的环境。学术机构、研究组织和临床医生之间加强合作，为加速核准週期和让患者更广泛地获得最先进治疗铺平了道路。从孤立的研究倡议转向更全面的跨职能策略，不仅会增加治疗方法创新，还能确保其以能够满足市场需求的弹性基础设施为基础。

市场区隔分析的关键见解

深入的細項分析揭示了关键见解，为市场动态提供了细緻的理解。该研究检验了不同类型的治疗策略，包括酵素替代疗法、基因疗法、药物疗法和小分子疗法。治疗方法的多样性反映了代谢疾病领域近期创新的广度和深度。据观察，治疗分类的重点反映了一种不断发展的治疗机制，旨在改善患者的治疗效果并根据个人需求量身定制医疗干预措施。

同时，透过观察疾病类型可以揭示市场分析的综合性。将糖尿病分为妊娠糖尿病、1 型糖尿病和第 2 型糖尿病等治疗方法凸显了专门护理途径的必要性。此外，它还包括高雪氏症、血铁沉着症、高胆固醇症、粒线体疾病、苯酮尿症 (PKU)、庞贝病以及细分为甲状腺功能亢进和甲状腺机能低下症的甲状腺疾病等。我们也正在严格研究其他重要疾病，例如尿素循环障碍和威尔森氏症，以确定每种疾病相关的独特挑战和治疗机会。

细分进一步扩展到治疗领域，详细说明主要影响内分泌系统、遗传框架和营养平衡的疾病。本节得出的见解表明，治疗方法的多样性与针对代谢紊乱的严重程度和进展而定制的多样化治疗方法组合直接相关。此外，根据给药途径（静脉注射、口服、皮下）进行细分可以帮助了解患者的便利性和药物的有效性。该分析还透过考虑成年人、老年人和儿童人群之间的差异来反映患者的人口统计。此外，专注于最终用户（无论是诊所、居家医疗机构、医院还是专科中心）可以进一步完善您的产品分销和可访问性策略。

综合评估还包括对分销管道的评估，包括医院药局、网路药局和零售药局。对这些主题进行综合分析，可以提供丰富的见解，阐明影响市场成长的潜在趋势。详细的细分方法不仅突出了治疗发现的方面，而且还规划了研发的策略性投资蓝图，以确保治疗创新与以患者为中心的结果紧密结合。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 生活方式和饮食习惯的改变导致代谢紊乱的发病率增加
      • 增加政府对代谢疾病监测的承诺与支持
    • 限制因素
      • 对产品召回和不利事件的担忧
    • 机会
      • CRISPR-Cas9 和其他基因组编辑工具在治疗代谢疾病方面的技术进步
      • 製药公司和医疗保健提供者之间合作和投资的增加正在提升潜力
    • 任务
      • 与专利到期以及取得和维护智慧财产权的复杂性相关的问题
  • 市场区隔分析
    • 治疗类别：基因治疗对代谢失调的益处日益增加
    • 疾病类型：口服药物在糖尿病治疗中的重要性日益增加
    • 治疗领域：代谢紊乱药物在治疗内分泌紊乱的成长潜力
    • 给药途径：对于口服吸收较差的药物，静脉注射有显着优势
    • 患者人口统计：增加成年患者代谢药物的使用，透过改变生活方式来防止病情进展
    • 最终用户：将代谢紊乱药物的使用范围从小型私人诊所扩大到大型多专科中心
    • 分销管道：网路药局因其便利性和选择性而变得越来越受欢迎。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 代谢紊乱药物市场（依治疗类别）

  • 酵素替代疗法
  • 基因治疗
  • 製药
  • 小分子疗法

第七章 代谢失调药物市场（依疾病类型）

  • 糖尿病
    • 妊娠糖尿病
    • 1型糖尿病
    • 2型糖尿病
  • 高雪氏症
  • 血铁沉着症
  • 高胆固醇症
  • 粒线体疾病
  • 苯酮尿症（PKU）
  • 庞贝氏症
  • 甲状腺疾病
    • 甲状腺功能亢进
    • 甲状腺机能低下症
  • 尿素循环障碍
  • 威尔逊氏症

第八章 代谢紊乱药物市场（依治疗领域）

  • 内分泌失调
  • 遗传性疾病
  • 营养障碍

第九章 代谢紊乱药物市场（依给药途径）

  • 静脉
  • 口服
  • 皮下

10. 代谢紊乱药物市场（依患者人口统计）

  • 成年患者
  • 老年患者
  • 儿科患者

第 11 章 代谢紊乱药物市场（依最终使用者）

  • 诊所
  • 居家照护环境
  • 医院
  • 专业中心

第 12 章代谢紊乱药物市场（按分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

13.美国代谢紊乱市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

14. 亚太代谢失调药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

15. 欧洲、中东和非洲代谢紊乱药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Amgen Inc.
  • Amicus Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici SpA
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Recordati Industria Chimica e Farmaceutica SpA
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
Product Code: MRR-0363DFE03688

The Metabolic Disorders Therapeutics Market was valued at USD 69.84 billion in 2023 and is projected to grow to USD 75.55 billion in 2024, with a CAGR of 8.35%, reaching USD 122.49 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 69.84 billion
Estimated Year [2024] USD 75.55 billion
Forecast Year [2030] USD 122.49 billion
CAGR (%) 8.35%

In the current landscape of healthcare innovation, metabolic disorders therapeutics have emerged as a critical focus area for researchers, clinicians, and policymakers. The unprecedented convergence of advanced scientific research and clinical applications has driven a renewed interest in effective treatment modalities for metabolic and endocrine disorders. As scientific breakthroughs continue to chart new territories in genetic editing, enzyme regulation, and personalized medicine, the dialogue between regulatory bodies and healthcare providers has matured. This executive summary delves into the transformative trends that are reshaping the therapeutic landscape, the nuanced segmentation of patient needs and disease intricacies, and the competitive dynamics among leading industry players. A comprehensive understanding of these elements is essential for stakeholders looking to navigate complexities, optimize resource allocation, and leverage emerging opportunities within this dynamic market.

The narrative that follows provides a holistic view of market trends and defines the strategic imperatives for both established industry giants and emerging participants. Drawing upon recent advancements and market data, this analysis articulates the evolution of metabolic disorders therapeutics from traditional approaches to modern, patient-centric solutions. It is an invitation to explore the interplay of rigorous scientific inquiry with robust market strategies and offers decision-makers a roadmap to drive sustainable growth in a rapidly advancing sector.

Transformative Shifts Shaping the Therapeutic Landscape

Recent years have witnessed transformative shifts in the metabolic disorders therapeutics landscape, largely propelled by innovations in biomedical research and shifts in regulatory frameworks. The advent of personalized medicine and the integration of digital technologies have accelerated the evolution from conventional treatment paradigms to more targeted therapeutic approaches. The market has experienced significant change driven by developments in both molecular biology and real-world evidence, which in turn have influenced treatment protocols and clinical best practices. Scientific advances in gene therapies, enzyme replacement therapies, and small molecule interventions have collectively contributed to streamlined patient care and improved clinical outcomes.

Technological breakthroughs in genetic sequencing and bioinformatics have enabled researchers to dissect disease mechanisms at a granular level, leading to the discovery of novel biomarkers and therapeutic targets. These innovations have dramatically shortened the cycle from research to product commercialization. As treatment protocols are honed to address complex metabolic disorders, the convergence of data analytics and patient monitoring is steadily redefining therapeutic landscapes. The integration of multidisciplinary insights has created opportunities for designing robust treatment regimens that are both efficacious and cost-effective, aligning with the strategic priorities of healthcare systems globally.

Furthermore, evolving regulatory policies have fostered an environment where rapid innovation is encouraged. Enhanced collaboration between academic institutions, research organizations, and clinical practitioners paves the way for faster approval cycles and broader patient access to cutting-edge therapeutics. This shift from siloed research initiatives to more integrated, cross-functional strategies ensures that treatment modalities are not only innovative but are also supported by a resilient infrastructure capable of scaling with market demands.

Key Insights from Market Segmentation Analysis

A deep-dive segmentation analysis uncovers important insights that provide a nuanced understanding of market dynamics. The study examines treatment strategies through the lens of various classifications, such as enzyme replacement therapies, gene therapies, medications and drugs, and small molecule therapy. This diverse range of treatment modalities illustrates the breadth and depth of recent innovations in addressing metabolic disorders. It is observed that the focus on treatment classifications speaks volumes about the evolving therapeutic mechanisms aimed at enhancing patient outcomes and tailoring healthcare interventions to individualized needs.

Simultaneously, an examination by disease type reveals the comprehensive nature of market analysis. Conditions like Diabetes Mellitus, with its subdivisions into gestational diabetes, Type 1 diabetes, and Type 2 diabetes, underscore the need for specialized treatment pathways. Additionally, the study encompasses a spectrum of disorders including Gaucher's Disease, Hemochromatosis, Hypercholesterolemia, Mitochondrial Disorders, Phenylketonuria (PKU), Pompe Disease, and a range of thyroid disorders that are further segmented into hyperthyroidism and hypothyroidism. Other notable conditions such as urea cycle disorders and Wilson's Disease are also rigorously explored to identify the unique challenges and therapeutic opportunities associated with each condition.

The segmentation further extends to therapeutic areas, underlining diseases predominantly affecting endocrine systems, genetic frameworks, and nutritional balance. Insights drawn from this section indicate that the variety of therapeutic avenues is directly linked to a diversified portfolio of treatment modalities that can be tailored to the severity and progression of metabolic disorders. An additional layer of segmentation based on the route of administration-be it intravenous, oral, or subcutaneous-provides an understanding of patient convenience and drug efficacy. The analysis also reflects upon patient demographics by considering differences among adult, geriatric, and pediatric populations. In addition, a focus on the end user, which spans clinics, home care settings, hospitals, and specialty centers, further refines strategies for product distribution and accessibility.

A comprehensive evaluation includes the assessment of distribution channels as well, encompassing hospital pharmacies, online pharmacies, and retail pharmacies. Each of these dimensions offers rich insights that, when collectively analyzed, reveal underlying trends influencing market growth. The detailed segmentation approach not only accentuates the granular aspects of treatment discovery but also charts out a roadmap for strategic investments in research and development, ensuring that therapeutic innovations align closely with patient-centric outcomes.

Based on Treatment Classifications, market is studied across Enzyme Replacement Therapies, Gene Therapies, Medications & Drugs, and Small Molecule Therapy.

Based on Disease Type, market is studied across Diabetes Mellitus, Gaucher's Disease, Hemochromatosis, Hypercholesterolemia, Mitochondrial Disorders, Phenylketonuria (PKU), Pompe Disease, Thyroid Disorders, Urea Cycle Disorders, and Wilson's Disease. The Diabetes Mellitus is further studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes. The Thyroid Disorders is further studied across Hyperthyroidism and Hypothyroidism.

Based on Therapeutic Areas, market is studied across Endocrine Disorders, Genetic Disorders, and Nutritional Disorders.

Based on Route Of Administration, market is studied across Intravenous, Oral, and Subcutaneous.

Based on Patient Demographics, market is studied across Adult Patients, Geriatric Patients, and Pediatric Patients.

Based on End User, market is studied across Clinics, Homecare Settings, Hospitals, and Specialty Centers.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Regional Dynamics and Global Market Insights

A regional analysis in the metabolic disorders therapeutics market reveals significant variances in demand, market maturity, and the pace of innovation. In regions such as the Americas, advanced healthcare infrastructure and high patient awareness have fueled strong adoption rates of new therapeutics. This region is characterized by a robust blend of clinical research, increased investment in pharmaceutical development, and proactive regulatory environments that collectively expedite the path from laboratory to market.

Conversely, the landscape in Europe, the Middle East, and Africa is marked by a balance between innovative therapies and traditional treatment modalities. In these areas, a multi-faceted strategy is observed where healthcare systems are progressively integrating modern treatment options with established protocols. The interaction between regulatory changes and evolving patient demographics offers a unique perspective that emphasizes the need for customization in therapeutic development. Incentives provided by both government and regional entities have supported the growth trajectory, while challenges include aligning new treatments with regional health priorities.

The Asia-Pacific region, on the other hand, is witnessing rapid modernization in healthcare facilities coupled with a surge in patient demand for advanced therapeutics. This region demonstrates a dynamic interplay between high population density and escalating incidences of metabolic disorders, driving significant market potential. Increasing investment in infrastructure and technology in these markets is a testament to the rising importance of metabolic disorders therapeutics globally. As regional collaborations expand and international partnerships flourish, the pace of market penetration is expected to accelerate, further bridging the gap between high-demand areas and advanced treatment capabilities.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Key Industry Players

The competitive landscape in metabolic disorders therapeutics is both vibrant and highly concentrated, with numerous established players exerting significant influence over market dynamics. Industry leaders, including Abbott Laboratories, AbbVie Inc., and Acadia Pharmaceuticals Inc., have leveraged their extensive research portfolios to drive innovation in treatment development. Amgen Inc. and Amicus Therapeutics, Inc. are renowned for their pioneering works in biologic therapies, while Astellas Pharma Inc. and AstraZeneca plc continue to redefine treatment paradigms through sustained investment in research and development.

Other influential companies such as Bayer AG, Biocon Limited, and BioMarin Pharmaceutical Inc. have established themselves as frontrunners in addressing rare and complex metabolic disorders. Boehringer Ingelheim International GmbH and CHIESI Farmaceutici S.p.A. demonstrate the power of cross-functional strategies and global partnerships in expanding therapeutic reach. Similarly, Dr. Reddy's Laboratories Ltd. and Eli Lilly and Company have made noteworthy strides by integrating cutting-edge technology with clinical precision. Firms like F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, and Glenmark Pharmaceuticals Limited are at the forefront of delivering improved care regimens across diverse patient groups.

The landscape is further enriched by contributions from Johnson & Johnson Services, Inc., Lupin Limited, and Luye Pharma Group Ltd, who continue to push the boundaries of therapeutic innovation. The dominance of Merck & Co., Inc., Novartis AG, and Novo Nordisk A/S is evident in their strategic market positioning and commitment to addressing multiple facets of metabolic disorders. With companies such as Otsuka Holdings Co., Ltd., Pfizer Inc., and Recordati Industria Chimica e Farmaceutica S.p.A. prioritizing research into disease-specific therapies, the market has become a crucible of competitive innovation. Additional significant contributors include Sanofi S.A., Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd., whose efforts further underscore the collective drive toward improved patient outcomes and clinical efficacy.

The synergy between these industry leaders fosters a competitive yet collaborative environment, which promises to sustain momentum and drive meaningful advancements in metabolic disorders therapeutics. This confluence of expertise and innovation ensures that the market remains resilient, dynamic, and capable of responding to evolving healthcare challenges through targeted and transformative strategies.

The report delves into recent significant developments in the Metabolic Disorders Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Acadia Pharmaceuticals Inc., Amgen Inc., Amicus Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Biocon Limited, BioMarin Pharmaceutical Inc., Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Lupin Limited, Luye Pharma Group Ltd, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co., Ltd., Pfizer Inc., Recordati Industria Chimica e Farmaceutica S.p.A, Sanofi S.A., Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd.. Actionable Strategies and Recommendations for Industry Leaders

Given the rapidly evolving nature of the metabolic disorders therapeutics market, industry leaders must adopt a proactive stance to maintain a competitive edge and drive sustainable growth. A key recommendation is to allocate resources toward strategic investments in research and development, particularly in areas that elucidate complex disease mechanisms and pave the way for innovative treatment protocols. Embracing collaborative alliances across academic institutions, biotech startups, and pharmaceutical giants can accelerate the pace of drug discovery and help mitigate the risks associated with clinical trial failures.

Leaders would benefit from harnessing the power of digital transformation to streamline patient engagement and enhance drug delivery systems. Incorporating data analytics and artificial intelligence into research processes can not only optimize clinical trials but also tailor treatments to individual patient profiles. As the market shifts towards personalized medicine, technology-driven strategies become essential to identifying potential treatment efficacies and predicting real-world outcomes.

To expand market reach, it is imperative to diversify distribution strategies by increasing the presence in both traditional and digital channels. Establishing robust networks that connect hospital settings, homecare environments, and specialty centers ensures broader patient access. Moreover, proactive engagement with regulatory bodies to secure favorable guidelines and expedited approval processes for innovative therapies can significantly reduce time-to-market. Industry leaders should closely monitor evolving healthcare policies and align their long-term strategies to accommodate emerging legal and ethical parameters.

Lastly, staying abreast of evolving patient demographics and lifestyle trends is crucial. An in-depth understanding of the diverse needs of adult, geriatric, and pediatric populations can guide product customization and ensure a better fit with the targeted therapeutic segments. By combining strategic foresight with agile operational models, companies are better poised to adapt to market changes and secure a leadership position in this increasingly competitive field.

Conclusion: Charting the Future of Metabolic Disorders Therapeutics

In summary, the metabolic disorders therapeutics market is undergoing a period of extensive transformation driven by rapid technological advancements and evolving patient-centric treatment strategies. The integration of novel therapies, refined segmentation insights, and robust regional dynamics has redefined the landscape in ways that not only improve clinical outcomes but also enhance overall market efficiency. The detailed analysis provided here underscores the importance of innovation, collaboration, and strategic resource allocation in addressing the multifaceted challenges posed by metabolic disorders.

The discussion has highlighted the critical role of segmentation in illuminating key market drivers, including treatment classifications, disease types, therapeutic areas, and patient demographics, which collectively shape the future trajectory of the industry. Furthermore, the examination of regional trends reveals diverse opportunities-ranging from the advanced healthcare ecosystems of the Americas and the balanced approach of Europe, the Middle East, and Africa to the burgeoning potential of the Asia-Pacific region. Industry leaders and innovators are thus encouraged to draw upon these insights to forge strategies that are both adaptive and forward-thinking.

This analysis concludes that the confluence of technological innovation, strategic partnerships, and evolving market dynamics provides a fertile ground for substantial growth. To harness this potential, stakeholders must be agile, informed, and prepared to invest in the long-term sustainability of therapeutic advancements for metabolic disorders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Shifting lifestyle and dietary patterns contributing to increased incidence of metabolic disorders
      • 5.1.1.2. Rising government initiatives and support for metabolic disorders research
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with product recall and adverse findings in medication
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in CRISPR-Cas9 and other genome-editing tools for treating metabolic disorders
      • 5.1.3.2. Growing potential with increasing collaborations and investments among pharmaceutical companies and healthcare providers
    • 5.1.4. Challenges
      • 5.1.4.1. Issues related to patent expirations and the complexity of obtaining and maintaining intellectual property
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Classifications: Increasing benefits of metabolic disorders therapeutics for gene therapies
    • 5.2.2. Disease Type: Proliferating significance of oral medications for treatment of diabetes mellitus
    • 5.2.3. Therapeutic Areas: Growing potential of metabolic disorders therapeutics for the treatment of endocrine disorders
    • 5.2.4. Route Of Administration: Significant advantages of intravenous for drugs that are poorly absorbed orally
    • 5.2.5. Patient Demographics: Increasing application of metabolic disorders therapeutics in adult patients owing to preventing progression through lifestyle modifications
    • 5.2.6. End User: Extending usage of metabolic disorders medications in clinics for small private practices to large multi-specialty facilities
    • 5.2.7. Distribution Channel: Rising popularity of online pharmacies owing to convenience and availability of options
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Metabolic Disorders Therapeutics Market, by Treatment Classifications

  • 6.1. Introduction
  • 6.2. Enzyme Replacement Therapies
  • 6.3. Gene Therapies
  • 6.4. Medications & Drugs
  • 6.5. Small Molecule Therapy

7. Metabolic Disorders Therapeutics Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Diabetes Mellitus
    • 7.2.1. Gestational Diabetes
    • 7.2.2. Type 1 Diabetes
    • 7.2.3. Type 2 Diabetes
  • 7.3. Gaucher's Disease
  • 7.4. Hemochromatosis
  • 7.5. Hypercholesterolemia
  • 7.6. Mitochondrial Disorders
  • 7.7. Phenylketonuria (PKU)
  • 7.8. Pompe Disease
  • 7.9. Thyroid Disorders
    • 7.9.1. Hyperthyroidism
    • 7.9.2. Hypothyroidism
  • 7.10. Urea Cycle Disorders
  • 7.11. Wilson's Disease

8. Metabolic Disorders Therapeutics Market, by Therapeutic Areas

  • 8.1. Introduction
  • 8.2. Endocrine Disorders
  • 8.3. Genetic Disorders
  • 8.4. Nutritional Disorders

9. Metabolic Disorders Therapeutics Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Metabolic Disorders Therapeutics Market, by Patient Demographics

  • 10.1. Introduction
  • 10.2. Adult Patients
  • 10.3. Geriatric Patients
  • 10.4. Pediatric Patients

11. Metabolic Disorders Therapeutics Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Homecare Settings
  • 11.4. Hospitals
  • 11.5. Specialty Centers

12. Metabolic Disorders Therapeutics Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Americas Metabolic Disorders Therapeutics Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Metabolic Disorders Therapeutics Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Metabolic Disorders Therapeutics Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Entero Therapeutics and Journey Therapeutics announce reverse merger to expand precision oncology and metabolic disorders therapies
    • 16.3.2. Chiesi Global Rare Diseases publishes phase 3 BRIGHT study results for pegunigalsidase alfa in fabry disease
    • 16.3.3. Sagimet's Denifanstat granted FDA advance therapy designation for MASH
    • 16.3.4. Amneal and Metsera collaborate to advance therapies for mbesity and Metabolic diseases
    • 16.3.5. Genespire secures USD 52.1m for gene therapy trial targeting rare metabolic disorder
    • 16.3.6. HAYA Therapeutics collaborates with Eli Lilly to target obesity and metabolic disorders using advanced rNA platform
    • 16.3.7. Roche acquires Carmot Therapeutics to advance in metabolic disease treatments
    • 16.3.8. ILBS and INSERM partner for advancements in metabolic disorder therapeutics
    • 16.3.9. Fractyl Health expands metabolic therapeutics pipeline with advanced clinical studies and preclinical results
    • 16.3.10. Marea Therapeutics launches with USD 190 million to develop next-gen cardiometabolic treatments
    • 16.3.11. Metsera strategic launch to innovate obesity and metabolic disease therapies
    • 16.3.12. Orchard Therapeutics U.S. launch of Lenmeldy for treating early-onset metachromatic leukodystrophy
    • 16.3.13. BioAge secures USD 170 million in Series D to advance obesity and metabolic therapies
    • 16.3.14. MIT secures USD 65.67 million for innovative metabolic disorder treatments
    • 16.3.15. Novo Nordisk collaborates with Omega Therapeutics and Cellarity on metabolic disorder innovations
    • 16.3.16. Chiesi Farmaceutici to acquire Amryt Pharma, enhancing rare disease therapeutics portfolio
  • 16.4. Strategy Analysis & Recommendation
    • 16.4.1. F. Hoffmann-La Roche Ltd
    • 16.4.2. Lupin Limited
    • 16.4.3. Eli Lilly and Company
    • 16.4.4. Pfizer Inc.

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Acadia Pharmaceuticals Inc.
  • 4. Amgen Inc.
  • 5. Amicus Therapeutics, Inc.
  • 6. Astellas Pharma Inc.
  • 7. AstraZeneca plc
  • 8. Bayer AG
  • 9. Biocon Limited
  • 10. BioMarin Pharmaceutical Inc.
  • 11. Boehringer Ingelheim International GmbH
  • 12. CHIESI Farmaceutici S.p.A.
  • 13. Dr. Reddy's Laboratories Ltd.
  • 14. Eli Lilly and Company
  • 15. F. Hoffmann-La Roche Ltd
  • 16. GlaxoSmithKline PLC
  • 17. Glenmark Pharmaceuticals Limited
  • 18. Johnson & Johnson Services, Inc.
  • 19. Lupin Limited
  • 20. Luye Pharma Group Ltd
  • 21. Merck & Co., Inc.
  • 22. Novartis AG
  • 23. Novo Nordisk A/S
  • 24. Otsuka Holdings Co., Ltd.
  • 25. Pfizer Inc.
  • 26. Recordati Industria Chimica e Farmaceutica S.p.A
  • 27. Sanofi S.A.
  • 28. Sumitomo Pharma Co., Ltd.
  • 29. Sun Pharmaceutical Industries
  • 30. Takeda Pharmaceutical Company Limited
  • 31. Teva Pharmaceutical Industries Ltd.
  • 32. Torrent Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. METABOLIC DISORDERS THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. METABOLIC DISORDERS THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. METABOLIC DISORDERS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. METABOLIC DISORDERS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY MEDICATIONS & DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GAUCHER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEMOCHROMATOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY MITOCHONDRIAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PHENYLKETONURIA (PKU), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY POMPE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY UREA CYCLE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY WILSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 174. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 176. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 183. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 184. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 185. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 190. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 192. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 193. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 194. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 199. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 201. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 202. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 203. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 205. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 208. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 210. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 211. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 212. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 214. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 217. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 219. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 220. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 221. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 223. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 236. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 238. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 239. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 240. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 242. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 245. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 247. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 248. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 249. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 251. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 254. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 256. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 257. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 258. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 259. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 260. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 263. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 265. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 266. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 267. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 269. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 272. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 274. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 275. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 276. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 278. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 281. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 283. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 284. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 285. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 287. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 289. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 290. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE